Apyx Medical Q3 net loss narrows 10% to $1.8 million as revenue rises 9% to $14 million
APYX•Apyx Medical’s third-quarter 2026 net loss attributable to stockholders narrowed 10% year over year to $1.8 million, while revenue rose 9% to $14 million. The company reaffirmed FY26 revenue guidance of $59 million to $60 million and lowered its operating expense forecast to $41 million to $42.5 million.
1. Quarterly results and outlook
Third-quarter revenue rose 9% to $14 million, including a 17% increase in Surgical Aesthetics revenue to $13 million. OEM revenue fell 42% to approximately $1.1 million due to lower sales volume to existing customers. Apyx Medical began the full commercial launch of the AYON system’s reusable power liposuction handpiece following positive feedback from early-adopter surgeons.
